Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord blood mononuclear cells (China Spinal Cord Injury Network)
- Development stage
- Unknown
- Lead developer
- China Spinal Cord Injury Network
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracerebral
01
Overview
Umbilical cord blood mononuclear cells (UCBMC) is a cell therapy being developed by the China Spinal Cord Injury Network for the treatment of chronic ischemic stroke. The treatment involves the surgical transplantation of a suspension containing 10 to 40 million viable mononuclear cells derived from umbilical cord blood into the brain tissue adjacent to the infarcted area. These cells are hypothesized to facilitate recovery by secreting neurotrophic factors, promoting angiogenesis, and modulating the local immune environment to support neural plasticity and repair in the chronic phase of stroke. The mononuclear cell fraction of umbilical cord blood contains a heterogeneous population of cells, including hematopoietic stem cells, mesenchymal stem cells, and various progenitor cells, which collectively contribute to tissue regeneration and functional recovery.
- Other names
- UCBMC-China Spinal Cord Injury Network-ischemic strokeUmbilical cord blood mononuclear cell transplantation
Beyond the preview
Go deeper on Umbilical cord blood mononuclear cells (China Spinal Cord Injury Network).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Umbilical cord blood mononuclear cells (China Spinal Cord Injury Network).